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Introduction
Tumour cells generally grow in a hypoxic environment.
They have to adapt their metabolism to the low availability
of oxygen by increasing glucose transport and glycolysis
to conserve sufficient ATP production. They also have to
trigger angiogenesis by producing angiogenic factors
such as vascular endothelial growth factor to facilitate
their vascularisation and to improve their oxygen supply.
These two adaptations are made possible by gene regula-
tion under the control of the transcription factor hypoxia-
inducible factor-1 (HIF-1) [1].
HIF-1 is a heterodimer made up of two subunits, HIF-1α
and HIF-1β (also called aryl hydrocarbon receptor nuclear
translocator, or ARNT). The HIF-1β protein is expressed
constitutively, whereas HIF-1α protein is not detectable in
cells under normoxic conditions although its coding
mRNA can be present [1]. In normoxia, the absence of
HIF-1α protein is due to proteasomal degradation by
means of the von Hippel–Lindau tumour suppressor
protein [1].
Although HIF-1α protein regulation has been well studied
[1], it is only lately that HIF-1α messenger regulation has
started to be documented [2]. Full-length HIF-1α mRNA
contains 15 exons, and a recent study has shown the exis-
tence of a splicing variant of HIF-1α mRNA lacking
exon 14 (sHIF-1α). The truncated HIF-1α protein obtained
aHIF = hypoxia-inducible factor 1α natural antisense; bp = base pairs; DFS = disease-free survival; dNTP = deoxyribonucleotide triphosphate;
HIF-1 = hypoxia-inducible factor 1; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; REx = relative expression; RT = reverse
transcription; SBR = Scarff, Bloom and Richardson; sHIF-1α = HIF-1α splice variant.
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Abstract
Background: Hypoxia-inducible factor-1α (HIF-1α) is part of a
transcriptional factor that regulates genes involved in metabolic
and vascular adaptation of tumours to oxygen restriction. A
splicing variant lacking exon 14 (sHIF-1α) encodes a truncated
protein that competes with the normal HIF-1α protein,
decreasing its activity. A natural antisense transcript (aHIF)
complementary to the 3′-untranslated region of HIF-1α mRNA
was described recently.
Methods: With a semiquantitative multiplex reverse
transcriptase–PCR (RT–PCR) assay, we assessed transcript
concentrations of HIF-1α, sHIF-1α and aHIF in 110 patients
with invasive breast carcinoma.
Results: We found a strong positive association between
HIF-1α and sHIF-1α, sHIF-1α and aHIF, and an inverse
correlation between HIF-1α/sHIF-1α and aHIF. aHIF transcript
expression was associated with poor disease-free survival in
univariate (P=0.0038) and multivariate (P=0.0016) analyses
in this series of high-risk primary breast carcinomas.
Conclusion: In our series of breast cancer patients, aHIF, and
not HIF-1α transcript, is a marker of poor prognosis.
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from this shorter mRNA is able to compete with the
normal HIF-1α protein for HIF-1β and therefore to
decrease HIF-1 transcriptional activity [3].
A natural antisense transcript (aHIF) complementary to the
3′-untranslated region of HIF-1α mRNA has been
described [4]. This sequence, which does not encode any
protein, is expressed in numerous human fetal and adult
tissues and in some tumours [5]. Expression of aHIF tran-
scripts might be involved in HIF-1α mRNA regulation and
therefore in HIF-1α protein synthesis.
Breast carcinoma is the most common cancer in women.
HIF-1α is considered to be a reliable prognostic and diag-
nostic marker for an increasing number of cancers from
various origins [6]. The aim of our study was to measure
correlations in vivo between HIF-1α mRNA, sHIF-1α and
aHIF, and to determine whether the concentrations of
these transcripts are associated with prognosis in human
breast cancer.
Materials and methods
Patients
One hundred and ten patients with previously untreated
primary invasive breast carcinoma were included in this
retrospective study. Initial staging comprised complete
and detailed clinical examination including the International
Union Against Cancer TNM (tumour size, nodes,
metastases) classification [7]. Ultrasound examination and
bilateral mammography were also performed. Histo-
pathological evaluation of the tumours was performed on
core needle biopsies by Scarff, Bloom and Richardson
(SBR) grading as modified by Elston and Ellis [8]. One
sample for each patient was used for DNA analysis by
flow cytometry with EPICS V (Beckman-Coulter, Roissy,
France). Tumour characteristics are reported in Table 1.
Under French law on biomedical research, this is an epi-
demiological study that does not have to be submitted to
an Institutional Review Board.
Treatments
After biopsy, all patients received neoadjuvant anthracycline-
based chemotherapy with doxorubicin (30–50mg/m2 at
day 1), pirarubicin (20mg/m2 at days 1 to 3) or epirubicin
(35–100mg/m2 at day 1), for six courses, the interval
between each course being 3 weeks. After induction
chemotherapy, patients underwent surgery, radiotherapy and
adjuvant tamoxifen for patients with oestrogen receptors.
Expression of HIF-1α α, sHIF-1α α and aHIF-1α α
Fine-needle aspirates were performed in 110 patients
diagnosed for breast cancer. An aliquot of each aspirate
was smeared on a slide to serve as a control, by a patholo-
gist, for the presence of malignant cells and the absence
of important stromal and fat contamination. Aspirates were
stored in liquid nitrogen until RNA extraction. Total RNA
was extracted with Trizol reagent (Gibco/BRL, Cergy-Pon-
toise, France). RNA was then stored at –80°C until cDNA
synthesis and amplification reaction. Reverse transcription
(RT) was performed at 42°C for 30 min in a 20µl reaction
mixture containing RNA, 1µl of each deoxyribonucleotide
triphosphate (dNTP) at 25mM (Gibco/BRL), 2µl of 10×
reaction buffer (67mM MgCl2, 166mM (NH4)2SO4,
670mM Tris-HCl at pH 8.8), 1µl of PdN6 random hexam-
ers (100µM; Roche, Meylan, France) and 200U of Mu-
MLV reverse transcriptase (Gibco/BRL). RT products
were diluted 1:25. Semiquantitative determination of
HIF-1α, sHIF-1α and aHIF transcript concentrations were
performed by RT–PCR with β2-microglobulin (β2) as an
internal control sequence. Each PCR reaction was per-
formed in a 50µl containing 5µl of the diluted RT product,
0.5µl of 25mM dNTPs, 5µl of 10× buffer II containing
15mM MgCl2 (Applied Biosystems, Courtaboeuf, France),
1.25U of AmpliTaq Gold (Applied Biosystems), 12.5pmol
of HIF-1α, 12.5pmol of aHIF and 25pmol each of β2
forward and reverse primers. With HIF-1α primers, two
amplicons were obtained, one of 486 base pairs (bp) cor-
responding to HIF-1α and one of 359bp corresponding to
sHIF-1α. The primers used are described in Table 2. In
preliminary experiments we determined the number of
cycles that allowed the linear simultaneous amplification of
the four different templates (up to 40 cycles). The opti-
mised PCR program was 94°C for 10 min, then 38 cycles
of 94°C for 50s, 60°C for 50s and 72°C for 20s, fol-
lowed by a final elongation step at 72°C for 10 min. PCR
reactions were run on a Masterblock Thermocycler
(Eppendorf, Le Pecq, France). Each RT–PCR product
(15µl) was loaded on a 6% polyacrylamide (19:1) gel
(QBiogen, Illkirch, France) and run for 3h at 120V in 1×
Tris-borate-EDTA. Images of the gels stained with ethid-
ium bromide were digitised with a digital video image
analyser (The IMAGER™; Appligene, Illkirch, France) and
analysed with the NIH Image 1.54 program for the Macin-
tosh. Results were expressed as the ratio of target gene
over β2 expression (relative expression, REx). PCR assays
were performed at least in duplicate for each sample, and
the results were averaged.
Immunohistochemical studies
The status of oestrogen and progesterone receptors,
HER2 and p53 were determined by immunohistochem-
istry on paraffin-embedded sections 3µm thick. The anti-
bodies, dilutions and antigen retrieval method used are
detailed in Table 3. Immunostaining was performed with a
Nexes automated immunostainer (Ventana, Illkirch,
France). Sections were scored semiquantitatively by light
microscopy by two pathologists. For oestrogen and prog-
esterone receptors and p53, a threshold of 10% of
stained nuclei was considered positive. For HER2, overex-
pression corresponded to more than 10% of cells
showing complete membrane staining with high intensity.R225
Statistics
The H test of Kruskal–Wallis was used to compare quanti-
tative and categorical parameters. When two quantitative
parameters were compared, Spearman’s rank correlation
test was used for abnormal distributions or unequal vari-
ances. Survival curves were designed with Kaplan–Meier’s
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Table 1
Patient and tumour characteristics and relationship with HIF-1α α, sHIF-1α α and aHIF mRNA expression concentration
Parameter Value n (%) HIF-1 sHIF-1 aHIF
Age (years) <50 55 (50) 0.25±0.03 P = 0.66 0.09±0.01 P = 0.53 0.23±0.05 P = 0.66
≥50 55 (50) 0.22±0.03 0.11±0.02 0.24±0.04
T stage 1 4 (4) 0.18±0.05 P = 0.49 0.04±0.01 P = 0.30 0.08±0.05 P = 0.010
2 73 (66) 0.22±0.03 0.09±0.01 0.26±0.02
3 21 (19) 0.16±0.03 0.08±0.02 0.45±0.07
4 12 (16) 0.31±0.03 0.20±0.02 0.45±0.13
Node status (clinical) – 43 (39) 0.15±0.03 P = 0.036 0.07±0.01 P = 0.11 0.21±0.05 P = 0.20
+ 66 (61) 0.25±0.03 0.12±0.02 0.25±0.04
Histological type IDC 91 (83) 0.23±0.03 P = 0.006 0.10±0.01 P = 0.74 0.21±0.03 P = 0.38
ILC 11 (10) 0.05±0.02 0.07±0.01 0.44±0.16
SBR grade I 13 (15) 0.24±0.07 P = 0.26 0.12±0.04 P = 0.20 0.31±0.14 P = 0.83
II 44 (50) 0.26±0.04 0.12±0.02 0.20±0.04
III 31 (35) 0.16±0.04 0.06±0.01 0.16±0.03
S phase <10% 48 (58) 0.22±0.04 P = 0.40 0.10±0.02 P = 0.97 0.19±0.06 P = 0.018
≥10% 35 (42) 0.19±0.04 0.08±0.02 0.28±0.05
Oestrogen receptors + 51 (56) 0.17±0.03 P = 0.02 0.09±0.02 P = 0.097 0.23±0.05 P = 0.49
– 40 (44) 0.29±0.04 0.12±0.02 0.22±0.05
Progesterone receptors + 24 (26) 0.18±0.04 P = 0.33 0.09±0.02 P = 0.14 0.26±0.09 P = 0.54
– 67 (74) 0.24±0.03 0.11±0.01 0.22±0.04
HER2 + 18 (21) 0.29±0.06 P = 0.039 0.13±0.03 P = 0.23 0.19±0.07 P = 0.92
– 66 (79) 0.17±0.03 0.08±0.01 0.23±0.05
p53 ≤10% 45 (75) 0.17±0.03 P = 0.20 0.08±0.02 P = 0.48 0.23±0.06 P = 0.37
>10% 15 (25) 0.22±0.04 0.07±0.01 0.21±0.07
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SBR, Scarff, Bloom and Richardson. For HIF-1, sHIF-1 and aHIF, results were
expressed by relative expression (REx) as mean±standard error (SE). The final sums are not always equal to 110 patients because of some non-
available data.
Table 2
Oligonucleotide sequences used for RT–PCR, and amplicon sizes
Oligonucleotide Direction Sequence Product size
HIF-1α Forward GTC GGA CAG CCT CAC CAA ACA GAG C 486 bp and 359 bp if exon 14 missing
Reverse GTT AAC TTG ATC CAA AGC TCT GAG
aHIF Forward TTT GTG TTT GAG CAT TTT AAT AGG C 279 bp
Reverse CCA GGC CCC TTT GAT CAG CTT
β2-microglobulin Forward CAT CCA GCG TAC TCC AAA GA 165 bp
Reverse GAC AAG TCT GAA TGC TCC ACmethod and compared with the log-rank test. We used the
5-year survival rate and Rothman’s 95% confidence inter-
val to document survival. A Cox proportional-hazards model
was used to investigate the simultaneous effect of
biopathological parameters (giving a probability (P) of less
than 0.10 with univariate analysis) on survival. P<0.05 was
considered significant. All tests were two-sided.
Results
Expression of HIF-1α α, sHIF-1α α and aHIF-1α α
REx values of HIF-1α, sHIF-1α and aHIF in breast tumours
were highly variable (Table 4). Expression of HIF-1α,
sHIF-1α and aHIF was detected in 85%, 86% and 72% of
the tumours, respectively. Strong positive correlations
between HIF-1α and sHIF-1α (P<10 –7) and sHIF-1α and
aHIF (P<10 –7) were found (Fig.1a, b). A weaker positive
correlation was observed between HIF-1α and aHIF
(P=4.3×10 –3; Fig.1c). Finally, a strong inverse correla-
tion between the HIF-1α:sHIF-1α ratio and aHIF  was
observed (P<2.5×10 –4; Fig.1d).
Relations between HIF-1α α, sHIF-1α α, aHIF-1α α, patient
and tumour characteristics
The relationship between clinicopathological variables and
each gene expression level are presented in Table 1.
HIF-1α was more highly expressed in node-positive
tumours than in node-negative tumours and in tumours
without oestrogen receptors (P=0.02). We also observed
Breast Cancer Research    Vol 5 No 6 Cayre et al.
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Table 3
Antibodies used for immunohistochemistry
Antibody Target Source Dilution Antigen-retrieval method Staining
6F11 Oestrogen receptor Tébu (Le Perray en Yvelines, France) 1:40 Pressure cooker, 3 min, citrate buffer pH 7.3 Nuclear
1α6 Progesterone receptor Tébu (Le Perray en Yvelines, France) 1:30 Pressure cooker, 3 min, citrate buffer pH 7.3 Nuclear
DA 485 HER2 Dako (Trappes, France) 1:1500 Water bath, 40 min, citrate buffer pH 6.0 Membrane
DO7 Wild-type and mutated p53 Dako (Trappes, France) 1:200 Pressure cooker, 3 min, citrate buffer pH 7.3 Nuclear
Table 4
Repartition of HIF-1α α, sHIF-1α α and aHIF relative expression in
breast tumours
Parameter HIF-1α sHIF-1α aHIF
Range 0–0.97 0–0.50 0–1.98
Mean±SE 0.21±0.02 0.10±0.01 0.23±0.03
Median 0.10 0.06 0.09
Interquartile interval 0.03–0.35 0.02–0.12 0–0.35
Figure 1
Association between relative expression (REx) values of HIF-1α, sHIF-1α and aHIF. (a) Correlation between REx of sHIF-1α and REx of HIF-1α
(P<10 –7). (b) Correlation between REx of HIF-1α and REx of aHIF (P=4.3×10 –3). (c) Correlation between REx of sHIF-1α and REx of aHIF
(P<10 –7). (d) Negative correlation between HIF-1α:sHIF-1α ratio and aHIF REx (P=2.5×10 –4).
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xa positive relation between HER2 and HIF-1α (P=0.039).
HIF-1α transcript expression in invasive ductal carcinoma
(IDC) was 4.5-fold that in invasive lobular carcinoma (ILC)
(P=0.006).
There was no relation between histological grade and
either HIF-1α or aHIF expression. No relation was seen
between aHIF, clinical node status, histological type,
oestrogen receptors, HER2 or p53. aHIF expression was
higher in tumours of more than 5cm (T3–T4) (P=0.01)
and in those with a high proliferation rate as measured by
S phase (P=0.018).
Given the large number of comparisons, a Bonferroni cor-
rection was performed for 30 comparisons (clinical vari-
ables with each transcript concentration), yielding
P=0.05/30=0.0017. In this instance, none of the corre-
lations maintained significance.
Predictive value of HIF-1α α, sHIF-1α α and aHIF-1α α
Pathological responses to neoadjuvant chemotherapy
were followed after surgical resection (data not shown).
None of HIF-1α, sHIF-1α or aHIF was predictive of treat-
ment response.
Prognostic value of HIF-1α α, sHIF-1α α and aHIF-1α α
At the time of analysis, 86 of 110 patients (78%) were still
alive, with a median follow-up of 61 months. As overall sur-
vival and disease-free survival (DFS) were similar, we com-
pared gene expression with DFS. Neither HIF-1α nor
sHIF-1α was related to survival in our series of breast
cancer patients. A significant association (P=0.0038)
between aHIF expression and DFS was obtained when
the three first quartiles were compared with the fourth
one. The breakpoint between high and low aHIF expres-
sion was REx=0.35, corresponding to the fourth quartile.
The first quartile could not be tested with DFS because it
contained only patients with null aHIF expression. The
median (REx=0.09) was tested and did not reach signifi-
cance (P = 0.059). The 5-year survival rate was 80% in
patients with low aHIF expression and 45% in patients
with high aHIF expression. The death risk for patients with
elevated aHIF transcript concentration was 2.8-fold that in
patients with a low concentration of HIF-1α antisense.
DFS was also significantly linked to oestrogen receptor
status (P=0.024), to SBR grade (P=0.023) and to
S phase (P=0.017) in univariate analyses. In multivariate
analysis (Cox regression model), aHIF remained an inde-
pendent prognostic marker (P=0.0016), with SBR grade
(P=0.0032), as shown in Table 5.
Discussion
HIF-1α is frequently overexpressed in primary and metasta-
tic human tumours [9]. In breast cancer, overexpression of
HIF-1α protein has been demonstrated in ductal in situ and
invasive carcinomas [9,10]. We have recently reported the
expression of aHIF transcript in breast tumours [5].
sHIF-1α is expressed in several human cell lines and in
human skin [3], but its expression in human tumours, espe-
cially in primary breast cancer, is still unknown.
In this study we examined 110 non-metastatic primary
breast cancers for the presence of HIF-1α, sHIF-1α and
aHIF, and we studied their relationship with the clinical
and biological behaviour and the prognosis of the
tumours.
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Table 5
Disease-free survival of 110 patients with primary invasive breast carcinoma
Univariate analysis Multivariate analysis (Cox)
5-year survival rate
Parameter Value RR (Rothman’s 95% CI) P RR 95% CI P
aHIF REx≤0.35 1 80% (70–87) 0.0038 1 1.5–7.4 0.0016
REx > 0.35 2.8 45% (26–66) 3.3
SBR grade 1 0 100% 0.023 1 1.1–4.6 0.0032
2 1 76% (62–87) 2.3 1.2–21.4
3 2 57% (39–73) 5.1
Oestrogen receptors + 1 82% (69–90) 0.024 1 0.9–5.2 n.s.
– 2.5 58% (42–72) 2.1
S phase ≤10% 1 81% (67–89) 0.017 1 0.6–3.7 n.s.
>10% 2.6 56% (39–71) 1.5
CI, confidence interval; n.s., not significant; REx, relative expression; RR, relative risk; SBR, Scarff, Bloom and Richardson.The high number of routinely studied parameters (oestro-
gen and progesterone receptors, HER2 and p53) in addi-
tion to the small size of the biopsies did not allow us to
test for the HIF-1α protein in our breast cancer samples.
Although HIF-1α and angiogenesis were closely linked
[11], in this study we focused on HIF-1α mRNA, its splic-
ing variant and their potential regulation by aHIF. We did
not evaluate angiogenesis because our 110 tumour
samples were core needle biopsies, and in most cases the
microvessel density could not be reliably assessed on a
core needle biopsy specimen [12].
Few studies have assessed HIF-1α in breast carcinoma.
Our data indicate that 85% of breast tumours expressed
HIF-1α mRNA. Others have studied HIF-1α in breast car-
cinoma by measuring protein expression by immunohisto-
chemistry. Zhong and colleagues found that only 29% of
primary breast carcinomas (15 of 52) expressed HIF-1α
protein, compared with 69% with lymph node metastasis
[9], whereas Bos and colleagues reported that 80% of
their invasive breast tumours (32 of 40) expressed HIF-1α
protein [10]. At the mRNA level, HIF-1α was detected in
71.7% of ovarian carcinomas (43 of 60) [13] and 100%
of glioblastomas (34 of 34) [14].
We established a negative relationship between HIF-1α
mRNA and oestrogen receptors. Such a relationship has
also been found between HIF-1α protein and oestrogen
receptors in cultured breast cell lines [15], even though
Bos and colleagues reported contradictory results [10].
An inverse correlation was reported between oestrogen
receptors and HIF-1β splicing variant in breast carcinoma
[16], but we did not observe such an association with
sHIF-1α.
In our study we demonstrated a positive relation between
HER2 and HIF-1α mRNA concentrations. A previous
study, performed on cultured cell lines, also found such a
correlation with HIF-1α protein, signifying that HER2 was
involved in promoting HIF-1α protein synthesis [17].
Another study showed a borderline association between
HIF-1α protein concentration and HER2 expression [10].
We found that HIF-1α mRNA expression in IDC was
4.5-fold that in ILC, and that 91% of ILC had no more than
1% relative HIF-1α mRNA expression. This is in accor-
dance with a recent study on [18F]fluorodeoxyglucose
uptake in human breast cancer, in which 86% of ILC had
no more than 1% HIF-1α protein [18].
We did not establish any relation between HIF-1α mRNA
expression and prognosis in breast cancer, as described
in the few reports that studied HIF-1α at the mRNA level
in ovarian carcinomas and glioblastomas [13,14]. On the
contrary, studies assessing HIF-1α protein by immunohis-
tochemistry have reported significantly poor prognosis in
head and neck and oropharyngeal carcinoma, in early
stage invasive cervical cancer, and in oligodendrogliomas
[19] (reviewed in [6]).
Because sHIF-1α encodes a shorter HIF-1α protein able
to interact with HIF-1β, thus forming a low-activity tran-
scription factor [3], one might expect that high concentra-
tions of sHIF-1α mRNA would be associated with a good
prognosis and a less aggressive tumour phenotype. This
was not observed in our study, even though among the
14 patients exhibiting the highest sHIF-1α REx (more than
0.29) only 1 (7%) died during the study period.
A unique aspect of our work was to measure the expres-
sion of aHIF transcript together with HIF-1α and sHIF-1α
in the same amplification reaction. The prognostic value of
HIF-1α mRNA was not observed in our series of
110 human breast cancers. However, we found that aHIF
seemed to be a strong independent prognostic marker in
this series. Moreover, aHIF expression was associated
with T3–T4 tumours and an S phase of more than 10%.
However, how aHIF expression interferes with HIF-1α
expression remains to be explained.
According to our observations, aHIF could be involved in
the regulation of HIF-1α mRNA expression at a post-tran-
scriptional level. Indeed, there is a strong negative associ-
ation (P<2.5×10 –4) between the ratio HIF-1α:sHIF-1α
and aHIF REx (Fig.1d). This might indicate that the greater
the amount of aHIF transcript present, the more HIF-1α
mRNA is spliced. Consequently, a smaller amount of full-
length HIF-1α mRNA is present. Another interpretation
based on previous results [5] would be that aHIF could
specifically destabilise HIF-1α mRNA but not sHIF-1α
transcript, resulting in larger amounts of the spliced form
for elevated amounts of aHIF.
The first significant study of HIF-1α protein concentrations
in cancer cells was published in 1999 [9]. Although the
correlation between HIF-1α overexpression and poor clini-
cal outcome is not systematic (reviewed in [6]), many
other studies both in humans and in animals have revealed
a direct involvement of HIF-1α in tumour progression
[10,20].
To consider HIF-1α as the unique parameter to be mea-
sured might be too reductionist. Indeed, it seems obvious
that other factors are involved in tumour progression or
resistance to treatments. If we focus on HIF-1α, HIF-1α
mRNA splicing variants have been shown to encode
shorter forms of HIF-1α that could compete with the
normal full-length protein [3]. Until now, HIF-1α detection
has been done essentially with immunohistochemistry,
with the use of antibodies that recognise either all forms of
the protein or only the full-length form of the protein.
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both types of antibody, to discriminate the full-length
protein from its shorter forms, which are apparently much
less deleterious. Thus, discriminating immunological tools
should be designed and made available.
Only a few studies with RT–PCR have been performed to
link HIF-1α mRNA expression and tumour-specific para-
meters [13,14], which is surprising because this kind of
study is able to discriminate between the different splicing
variants of HIF-1α, even though it does not indicate the
presence of the protein.
Finally, detection of a protein does not indicate whether
this protein is active. Indeed, a protein inhibitor of HIF-1α
has recently been described and identified as the
asparagine hydroxylase known to block the interaction
between p300 and HIF-1 [21]. One could therefore
imagine that large amounts of this protein could easily
inhibit large amounts of HIF-1α.
Conclusion
This work shows that aHIF is a poor prognosis marker in
breast cancer. It seems to participate in HIF-1α mRNA
regulation, perhaps by affecting the amount of the spliced
form (see Fig.2 for a summary). HIF-1α is part of a tran-
scription factor controlling the expression of more than
50 target genes whose products have crucial functions in
tumour progression, angiogenesis, the maintenance of
ATP production in cells, anti-apoptosis, and so on.
Changes in its regulation will therefore have conse-
quences for each of the above processes. In this time of
targeted therapeutics for breast cancer (anti-HER2, anti-
angiogenesis), it seems promising to study the regulation
of a factor governing such targets.
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